LONG-TERM EFFICACY OF DUPILUMAB IN ORAL CORTICOSTEROID-DEPENDENT PATIENTS WITH ASTHMA: LIBERTY ASTHMA TRAVERSE

TOPIC: Obstructive Lung Diseases TYPE: Original Investigations PURPOSE: Many patients with severe asthma driven by type 2 inflammation require long-term treatment systemic corticosteroids. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/13, key and central drivers of inflammation. Dupilumab is approved in US as an add-on moderate-to-severe aged ≥12 years eosinophilic phenotype or oral corticosteroid (OCS)–dependent asthma. In phase 3 OCS-sparing VENTURE (NCT02528214) study, dupilumab 300 mg every weeks (q2w) vs placebo significantly reduced OCS use adults/adolescents OCS-dependent protocolized fashion over 24 weeks. LIBERTY ASTHMA TRAVERSE (NCT02134028), single-arm, open-label extension evaluated dupilumab’s safety, tolerability, efficacy rolled from previous study. This post hoc analysis assessed ability to sustain reduction that was achieved during VENTURE, long term population OCS-dependent, METHODS: treated q2w who enrolled received 300mg up 96 Endpoints dupilumab/dupilumab-treated placebo/dupilumab-treated included mean dose throughout TRAVERSE. Additional endpoints proportion discontinued OCS, <5 ≥50% end maintained this duration Efficacy were exacerbation rate change pre-BD FEV1 baseline. RESULTS: Of 210 patients, 187 after completing VENTURE. At 27% compared placebo. By Week 48 TRAVERSE, reductions baseline observed 78% 53% these sustained (89%, dupilumab/dupilumab; 74%, placebo/dupilumab). 0 (48/90) 30% (29/97) use, 74% (67/90) 38% (37/97) mg, 82% (74/90) 54% (52/97) clinically meaningful use. Most discontinuation at Weeks Despite requirements, rates low improvements sustained. CONCLUSIONS: The effect demonstrated CLINICAL IMPLICATIONS: may maintain while improving DISCLOSURES: Employee relationship Sanofi Please note: >$100000 Nadia Daizadeh, source=Web Response, value=salary shares Genzyme 2018-2021 Added 05/04/2021 Megan Hardin, value=Salary current employee 04/30/2021 Elizabeth Laws, source=Admin input, Consultant Veracyte $5001 - $20000 David Lederer, value=Consulting fee Removed Response Roche $1-$1000 Advisory Committee Member Boehringer-Ingelheim value=0 Galapagos Fibrogen Global Blood Therapeutics $1001 $5000 Galecto value=Travel Regeneron July 2019 Stock/Stock options value=Stock/Stock 2000-2021 Leda Mannent, 09/02/2014 Xuezhou Mao, No relevant relationships jorge maspero, Pharmaceuticals Inc. Benjamin Ortiz, Namrata Pandit-Abid, Scientific Medical Advisor Boehringer Ingelheim Klaus Rabe, AstraZeneca value=Grant, Honoraria Travel Novartis Chiesi fee, Honoraria, Tra value=Honoraria, Travel, Grant Grant, Travelstock holder since 2016 05/10/2021 Marcella Ruddy, March presen Aimmune Therapeutics, Optinose, Pharmaceuticals, Inc., 10 05/05/2021 Lawrence Sher, Board TBD Speaker/Speaker's Bureau value=Honoraria Amgen, AstraZeneca, Circassia, DBV Technologies, Galderma, GSK, Lupin, Merck value=Grant/Research Support Mylan, Novartis, Novo Nordisk, Pearl Pfizer, Pulmagen, Roxane, Spirometrix, Teva, Vectura, Watson Personal fees Teva 04/26/2021 Michael Wechsler, GSK Equillium Cohero Health